CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.
Medicare faces evolving opportunities and challenges in covering weight loss drugs through legislation like the Treat and Reduce Obesity Act and federal demonstration projects. Drug adherence and cost-effectiveness remain key issues.
Celebrity health journeys reveal critical insights into obesity risks, chronic disease management, and insurance implications for older Americans.
The Treat and Reduce Obesity Act introduces expanded Medicare coverage for obesity screenings, specialists, and medications, aiming to reduce obesity-related diseases and healthcare costs among seniors.
CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.
Maine advocates seek Medicare coverage for anti-obesity medications to improve public health, reduce healthcare costs, and promote active transportation. Bipartisan support grows with Senator Susan Collins' leadership.
